Plasma protein treatments are used to treat a variety of hereditary, uncommon, and chronic illnesses. Plasma, enzymes, salts, antibodies, proteins, and water are all components of plasma protein therapies, which might vary depending on how they are produced and processed. Animal bites, autoimmune and immunological deficits, neurological and bleeding conditions, and shocks and burns are all treated with them.
The market worth of plasma protein therapeutics in 2021 was USD 27.20 billion, and it will be worth USD 50.4 billion by 2030, growing at a 7.1% CAGR during the forecast period.
The market for plasma protein therapeutics is anticipated to be driven by rising investments in innovation, rising immunoglobulin (IG) demand, rising indications, and increasing therapeutic use of plasma derived protein therapeutics.
The market is now seeing an increase in demand for sophisticated therapeutic treatments due to the plasma protein’s useful features fueling the industry’s expansion. Additionally, the market is expanding because the government supports the development of the healthcare sector and the favorable reimbursement practices of health insurance investment firms. The development of plasma protein therapies and the production of sophisticated delivery systems for these therapeutic treatments, combined with ongoing technological improvements in the extraction and separation of plasma, are driving the worldwide plasma protein therapeutics market.
The implementation of plasma therapy may be hampered by the imposition of rigid guidelines and rules for handling plasma protein products and by the absence of reimbursement plans. These are the main factors hindering the market for plasma protein therapies from expanding.
In the coming years, opportunities may arise as people become more aware of autoimmune diseases, organ transplants (such as liver surgery and pediatric HIV), and cases of burns that result in trauma among people. Per the National Institutes of Health, the number of Americans with an autoimmune disease is 23.5 million, or more than 7% of the population. The government’s plasma regulations may open up many opportunities for the market’s future expansion.
The plasma protein therapies market is divided into albumin, immunoglobulins (IG), plasma-derived factor VIII, and others based on the kind of product. Immunoglobulin ruled the entire market, with a more than 45.42% share in 2021. The widespread acceptance of biologics for various purposes, simplicity of administration, and high cost of care are all to blame for the high percentage.
The enhanced detection of hypoalbuminemia brought on by liver cirrhosis and hepatitis B will contribute to the albumin segment’s large market growth during the projection period.
In 2020, the Haemophilia sector held the greatest market share of nearly 45%. More than 1,125,000 men worldwide suffer from an inherited bleeding illness, and 418,000 of them have a severe form of the most underdiagnosed disease, according to the Global Hemophilia Care report. Factors like the rising number of life-threatening diseases, the growing geriatric population, changes in dietary habits, and the adoption of a sedentary lifestyle are driving the segment’s overall expansion. 241,535 people with hemophilia, either Type A or Type B, were among the 393,658 people surveyed for the worldwide health survey, according to the World Federation of Hemophilia report 2020.
Asia Pacific, North America, Europe, the Middle East and Africa, and Latin America are the geographical divisions of the market. North America and Europe contributed to the largest market share of 70.26%. The U.S. led the North American regional market with a market share of more than 40.47% in 2021. Some of the important geographical drivers include the presence of a sizable patient base, an increasing geriatric population, and the availability of a well-developed infrastructure for storing and keeping high-quality source plasma. Some other major regional expansion drivers include rising disease prevalence and increased use of innovative therapies.
- Biotest AG
- Takeda Pharmaceutical Company Ltd
- Octapharma USA Inc.
- China BiologicProducts Holdings Inc.
- Grifold, SA
- CSL Behring
- Al Company Ltd
The market worth of plasma protein therapeutics in 2021 was USD 27.20 billion, and it will be worth USD 50.4 billion by 2030, growing at a 7.1% CAGR during the forecast period. The market is growing due to the rising incidence of autoimmune diseases, immune deficiency disorders, and bleeding disorders and the expanding use of plasma protein treatment in neurology and other therapeutic purposes.